Clinical Trials Directory

Trials / Completed

CompletedNCT02730637

Prevention of Acute Kidney Injury Through Biomarker-guided Nephrological Intervention

Prevention of Acute Kidney Injury Through Biomarker-guided Nephrological

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
100 (actual)
Sponsor
Robert Bosch Medical Center · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study examines the clinical relevance of early biomarkers to detect and prevent acute kidney injury. High-risk patients for developing acute kidney injury will be screened at initial presentation (emergency department and intensive care unit) for TIMP2xIGFBP7. In case of elevated readings patients will be randomized in two arms: The control group will be treated with standard care, the intervention group will receive an early nephrologic consultation.

Detailed description

This study examines the impact of an early biomarker-guided intervention on the development of acute kidney injury (AKI). New biomarkers indicate kidney damage in an early stage before developing acute kidney injury according to AKI Kidney Disease Improving Global Outcomes (KDIGO) Definition is detectable. The investigators want to test if it's possible to prevent AKI based on elevated urinary biomarkers. Eligible patients will be randomly assigned to two groups, a control and an intervention Group by an early nephrologic consultation. The interventional group will receive an early preventive nephrologist consultation additionally to standard care.

Conditions

Interventions

TypeNameDescription
OTHEREarly nephrologist consultation

Timeline

Start date
2016-03-01
Primary completion
2017-10-01
Completion
2017-11-01
First posted
2016-04-06
Last updated
2017-12-15

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT02730637. Inclusion in this directory is not an endorsement.